Aim: To highlight Tamoxifen and ovarian suppression as effective adjuvant approaches for premenopausal steroid receptor-positive breast cancer. In addition to encourage surgeons toward breast-conserving surgery with this effective adjuvant approaches. Patients and Methods: Premenopausal women with early stages, steroid hormone receptor– positive breast cancer, 100 selected patients, for retrospective study were randomly assigned to six or eight cycles of chemotherapy. Followed by two years of monthly Goserelin, and daily Tamoxifen for five years. The primary endpoints were time to recurrence (TTR) for Tamoxifen alone therapy versus combined Tamoxifen and Goserelin therapy. Results: With two year follow-up, the combination of Tamoxifen and Goserelin show improved time to recurrence (TTR). Conclusion: Combination of Tamoxifen and Goserelin improves outcome for premenopausal stage1, II and IIIA, hormone receptor-positive breast cancer